Lilly/Isis Lung Cancer NDA Possible In 2003; Lymphoma Indication In Phase II

An NDA for the Isis drug 3521, licensed to Eli Lilly, could be submitted for non-small cell lung cancer by 2003.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet